Restoring receptor signalling
Its antibodies bring receptor components together to correct signalling impaired by disease-causing mutations. The lead programme, DIAG723, targets hereditary haemorrhagic telangiectasia and pulmonary arterial hypertension.
Moving from preclinical work
At the financing, DIAG723 had been tested in preclinical disease models. Diagonal planned its first human study in HHT during the first half of 2026.
Where the funding goes
- Advance clinical development of DIAG723 and additional clustering-antibody candidates.